Le Lézard
Classified in: Health
Subjects: AWD, SCZ

A Culture Of Caring: CareCentrix Named A 2019 Top Workplace By Tampa Bay Times


TAMPA, Fla., April 7, 2019 /PRNewswire/ -- CareCentrix, the leading provider of home-based post-acute care solutions, is selected as one of the Tampa region's top employers, according to the Tampa Bay Times 2019 Top Workplaces ranking; over half of CareCentrix's more than 800 Tampa region employees completed the survey.  The employee survey gathers responses on 24 factors covering seven areas, including organizational health factors that measure how well employees are working together towards a common cause:

"CareCentrix is dedicated to building a culture of caring, and a progressive environment in which every individual can achieve professional goals while also fulfilling personal purpose," said John Driscoll, chief executive officer, CareCentrix.  "Our programs drive employee engagement, offer benefits that matter, and make a difference to people," said Driscoll.  "Caring is fundamental to our DNA." 

CareCentrix's employee benefits package includes:

"Top Workplaces is more than just recognition," said Doug Claffey, CEO of Energage, the company that administers the survey. "Our research shows organizations that earn the award attract better talent, experience lower turnover, and are better equipped to deliver bottom-line results. Their leaders prioritize and carefully craft a healthy workplace culture that supports employee engagement."

About CareCentrix
CareCentrix is the leading manager of post-acute services with a core focus of making the home a center of care.  With over 20 years' experience and over 26 million members under management, CareCentrix is recognized by its payor customers for our innovative approaches to improving quality and reducing costs across the post-acute service continuum.  Using advanced analytics and technology, CareCentrix is able to determine the appropriate site of care along each point of the healing and aging process in order to support patients, their families and the providers throughout the care transition process.  With over 8,000 providers in our network, CareCentrix coordinates services through post-acute facilities and home-based service providers including home health, durable medical equipment, home infusion and home sleep.  For more information, please visit http://www.CareCentrix.com.

About Energage, LLC
Headquartered in Exton, Pa., Energage is a leading provider of technology-based employee engagement tools that help leaders to unlock potential, inspire performance, and achieve amazing results within their organizations. The research partner behind the Top Workplaces program, Energage has surveyed more than 57,000 organizations representing well over 19 million employees in the United States.

SOURCE CareCentrix


These press releases may also interest you

at 07:10
Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended...

at 07:10
Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, today announced the appointments of global leaders in cell therapy and drug development, Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to its board of directors....

at 07:05
Aldeyra Therapeutics, Inc. (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the clinical development plan intended to enable...

at 07:05
Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, announced that George Eliades, Ph.D., has joined the...

at 07:05
Seres Therapeutics, Inc. ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on March 25, 2024, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants covering an...

at 07:05
Gilead Sciences, Inc. and Xilio Therapeutics, Inc. today announced an exclusive license agreement to develop and commercialize Xilio's Phase 1 tumor-activated IL-12 program, XTX301. Xilio Therapeutics is a clinical-stage biotechnology company...



News published on and distributed by: